Abstract
Antibody-drug conjugates (ADCs) for solid tumor indications have traditionally employed microtubule disrupting agents. We recently demonstrated utility of calicheamicin, a double-strand DNA break inducing payload, when conjugated to an antibody targeting a cell surface antigen expressed on the surface of cancer stem cells (CSCs) or tumor-initiating cells (TICs) and Ephrin-A4 (EFNA4). When tested in preclinical models of breast and ovarian cancer, the hydrazone linker-based calicheamicin conjugate (PF-06647263) displayed robust antitumor activity, and the compound is currently being evaluated for clinical benefit to cancer patients. Calicheamicin is a member of a highly potent enediyne class of deoxyribonucleic acid (DNA)-damaging cytotoxic natural products with a unique mechanism of action that involves scission of DNA. Two additional calicheamicin-based ADCs are in late-stage clinical development, including the ADC, inotuzumab ozogamicin, targeting CD22-positive, liquid tumors including NHL and ALL, and the CD33-targeting gemtuzumab ozogamicin, targeting AML.
The recent expansion of the utility of calicheamicin conjugates to solid tumors may have a broader impact on ADC development, as their mechanism of action leading to tumor cell death is entirely different from microtubule disrupting agents. In particular, calicheamicin impacts quiescent or dormant cells as well as cycling cells, whereas microtubule inhibitors impact only cycling cells. Herein, we review the mechanism and key pharmacological findings of calicheamicin conjugates targeting liquid and solid tumors and discuss potential areas for future development of calicheamicin conjugates.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14:529–537
Bellomo G, Vairetti M, Stivala L, Mirabelli F, Richelmi P, Orrenius S (1992) Demonstration of nuclear compartmentalization of glutathione in hepatocytes. Proc Natl Acad Sci U S A 89(10):4412–4416
Bernstein ID (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14:474–475
Bouchard H, Viskov C, Garcia-Echeverria C (2014) Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett 24:5357–5363
Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F, Lo Coco F (2007) Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 92:1273–1274
Burleigh A, McKinney S, Brimhall J, Yap D, Eirew P, Poon S, Ng V, Wan A, Prentice L, Annab L et al (2015) A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Res 17:4
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701
Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379:1508–1516
Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V et al (2015) Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin Cancer Res 21:4165–4173
Damle NK (2004) Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 4:1445–1452
de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH (2012) The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26:255–264
Dedon PC, Goldberg IH (1992) Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chem Res Toxicol 5:311–332
DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al (2004a) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807–1814
DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK (2004b) Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 10:8620–8629
DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res 12:242–249
Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21:2240–2245
DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK (2011) Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol 67:741–749
Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67:1048–1053
Drak J, Iwasawa N, Danishefsky S, Crothers DM (1991) The carbohydrate domain of calicheamicin gamma I1 determines its sequence specificity for DNA cleavage. Proc Natl Acad Sci U S A 88:7464–7468
Du W, Yu W, Huang L, Zhao M, Li X (2012) Ephrin-a4 is involved in retinal neovascularization by regulating the VEGF signaling pathway. Invest Ophthalmol Vis Sci 53:1990–1998
Ellestad GA (2011) Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ1I. Chirality 23:660–671
Eramo A, Haas TL, De Maria R (2010) Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29:4625–4635
Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R (1987) Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 317:468–473
Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spisek R (2011) Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71:4821–4833
Gerber HP, Koehn FE, Abraham RT (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30:625–639
Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8:521–534
Grimwade D, Enver T (2004) Acute promyelocytic leukemia: where does it stem from? Leukemia 18:375–384
Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T (2004) Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clinical Chem 50:490–499
Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D et al (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13:47–58
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986–996
Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53:3336–3342
Ho SN, Boyer SH, Schreiber SL, Danishefsky SJ, Crabtree GR (1994) Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proc Natl Acad Sci U S A 91:9203–9207
Hoelzer D (2014) Dose-adjusted EPOCH-R for Burkitt lymphoma. Clin Adv Hematol Oncol 12(11):777–779
Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ (1995) Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci U S A 92:10506–10510
John B, Herrin BR, Raman C, Wang YN, Bobbitt KR, Brody BA, Justement LB (2003) The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J Immunol 170:3534–3543
Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72
Lee CM, Haun RS, Tsai SC, Moss J, Vaughan M (1992) Characterization of the human gene encoding ADP-ribosylation factor 1, a guanine nucleotide-binding activator of cholera toxin. J Biol Chem 267:9028–9034
Lin CC, Anseth KS (2011) Cell-cell communication mimicry with poly(ethylene glycol) hydrogels for enhancing beta-cell function. Proc Natl Acad Sci U S A 108:6380–6385
Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M et al (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104:1995–1999
Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N et al (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30:1147–1158
McCulloch EA (1983) Stem cells in normal and leukemic hemopoiesis (Henry Stratton lecture, 1982). Blood 62:1–13
Moss A, Alvares D, Meredith-Middleton J, Robinson M, Slater R, Hunt SP, Fitzgerald M (2005) Ephrin-A4 inhibits sensory neurite outgrowth and is regulated by neonatal skin wounding. Eur J Neurosci 22:2413–2421
Mullard A (2013) Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 12:329–332
Muller AM, Duque J, Shizuru JA, Lubbert M (2008) Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 27:5759–5773
Nicolaou KC, Smith AL, Yue EW (1993) Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci U S A 90:5881–5888
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS (2006) A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Investig 35:93–114
Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6:462–475
Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10:165–180
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al (2012) Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 119:3705–3711
Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17:6417–6427
Rosfjord E, Lucas J, Li G, Gerber HP (2014) Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol 91:135–143
Sapra P, Hooper AT, O’Donnell CJ, Gerber HP (2011) Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 20:1131–1149
Shor B, Gerber HP, Sapra P (2015) Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol 67:107–116
Surawska H, Ma PC, Salgia R (2004) The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15:419–433
Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482–491
Thorson JS, Sievers EL, Ahlert J, Shepard E, Whitwam RE, Onwueme KC, Ruppen M (2000) Understanding and exploiting nature’s chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 6:1841–1879
Walter RB, Appelbaum FR, Estey EH, Bernstein ID (2012) Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119:6198–6208
Zein N, Sinha AM, McGahren WJ, Ellestad GA (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198–1201
Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806–823
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Gerber, HP., Damelin, M., Sapra, P. (2017). Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications. In: Grawunder, U., Barth, S. (eds) Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-46877-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-46877-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46875-4
Online ISBN: 978-3-319-46877-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)